About Obsidian Therapeutics
Obsidian Therapeutics is a company based in Cambridge (United States) founded in 2015. It operates as a HealthTech. Obsidian Therapeutics has raised $325 million across 3 funding rounds from investors including Amgen, TD Securities and Citadel. The company has 80 employees as of December 31, 2022. Obsidian Therapeutics offers products and services including OBX-115 and cytoDRiVE® Platform. Obsidian Therapeutics operates in a competitive market with competitors including BeiGene, Serum Institute of India, Senti Biosciences, TScan Therapeutics and Vir Biotechnology, among others.
- Headquarter Cambridge, United States
- Employees 80 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Obsidian Therapeutics, Inc.
-
Annual Revenue
$639.91 (USD)-47as on Jul 31, 2023
-
Net Profit
-$612.02 (USD)-146as on Jul 31, 2023
-
EBITDA
Not available
-
Total Equity Funding
$325 M (USD)
in 3 rounds
-
Latest Funding Round
$160.5 M (USD), Series C
Apr 03, 2024
-
Investors
Amgen
& 24 more
-
Employee Count
80
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Obsidian Therapeutics
Obsidian Therapeutics offers a comprehensive portfolio of products and services, including OBX-115 and cytoDRiVE® Platform.
An investigational therapy for advanced melanoma treatment.
A platform for controlling therapeutic protein functions.
People of Obsidian Therapeutics
Unlock access to complete
Unlock access to complete
Leadership Team
23 people
Scientific Team
8 people
Product Management Team
7 people
Software Development Team
4 people
Finance and Accounting
3 people
Human Resources and Administration
2 people
Senior Team
2 people
Sales and Marketing
1 people
Unlock access to complete
Funding Insights of Obsidian Therapeutics
Obsidian Therapeutics has successfully raised a total of $325M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $160.5 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Obsidian Therapeutics
Obsidian Therapeutics has secured backing from 25 investors, including institutional and venture fund investors. Prominent investors backing the company include Amgen, TD Securities and Citadel.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multi-stage investment firm invests in healthcare and life sciences companies
|
Locked | Locked | Locked | |
|
Multiple sectors are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
Private equity and venture capital fund focused on the healthcare sector
|
Locked | Locked | Locked |
Investor details for Obsidian Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Obsidian Therapeutics
Investment portfolio details for Obsidian Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Obsidian Therapeutics
Detailed financials for Obsidian Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Obsidian Therapeutics Comparisons
Peer comparison for Obsidian Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Obsidian Therapeutics
Obsidian Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BeiGene, Serum Institute of India, Senti Biosciences, TScan Therapeutics and Vir Biotechnology, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Vaccines and immuno-biological drugs for infectious diseases are manufactured.
|
|
| Locked | Locked | Locked |
Cell-based therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of infectious diseases
|
|
| Locked | Locked | Locked |
Immunotherapeutics for cancer and other diseases are developed.
|
Detailed competitors of Obsidian Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Obsidian Therapeutics
Complete news archive for Obsidian Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Obsidian Therapeutics
Obsidian Therapeutics was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Obsidian Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Michael Gilman is the current CEO of Obsidian Therapeutics.
Obsidian Therapeutics is a funded company, having raised a total of $325M across 3 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Obsidian Therapeutics is 80.
Annual revenue of Obsidian Therapeutics is $639.91 as on Jul 31, 2023.
Obsidian Therapeutics is engaged in pioneering cell and gene therapy solutions. The company is recognized for leading the next generation of engineered therapeutics. Its proprietary cytoDRiVE platform is utilized to control protein function with FDA-approved small molecules. A novel pipeline of therapeutics is being developed, including the lead clinical program OBX-115 for advanced melanoma. Collaborations are established to enable discovery of innovative therapies. The focus is placed on precision medicines to address patient needs across various healthcare sectors.
Obsidian Therapeutics's top competitors include BeiGene, BioNTech and Senti Biosciences.
Obsidian Therapeutics offers OBX-115 and cytoDRiVE® Platform.
Obsidian Therapeutics has 25 investors. Key investors include Amgen, TD Securities, Citadel, Janus Henderson Investors, and RTW Investments.